447 related articles for article (PubMed ID: 9012929)
1. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.
Nicholson VA; Whimbey E; Champlin R; Abi-Said D; Przepiorka D; Tarrand J; Chan K; Bodey GP; Goodrich JM
Bone Marrow Transplant; 1997 Jan; 19(1):37-41. PubMed ID: 9012929
[TBL] [Abstract][Full Text] [Related]
2. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
[TBL] [Abstract][Full Text] [Related]
3. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
[TBL] [Abstract][Full Text] [Related]
4. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
[TBL] [Abstract][Full Text] [Related]
5. The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation.
Humar A; O'Rourke K; Lipton J; Messner H; Meharchand J; Mahony J; Walker I; Wasi P; McGeer A; Moussa G; Chua R; Mazzulli T
Bone Marrow Transplant; 1999 Jan; 23(1):45-51. PubMed ID: 10037050
[TBL] [Abstract][Full Text] [Related]
6. Early treatment of CMV antigenemia with ganciclovir for prevention of fatal CMV disease in patients receiving marrow from HLA-matched unrelated donors.
Shimokawa T; Morishima Y; Kitaori K; Kato C; Sao H
Int J Hematol; 1999 Aug; 70(2):119-26. PubMed ID: 10497851
[TBL] [Abstract][Full Text] [Related]
7. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
Murray BM; Subramaniam S
Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L
Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338
[TBL] [Abstract][Full Text] [Related]
9. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
10. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus viral load monitoring after allogeneic bone marrow transplantation in patients receiving antiviral prophylaxis.
Howden BP; Michaelides A; Spelman DW; Spencer A; Schwarer AP; Wesselingh S; Kotsimbos TC
Bone Marrow Transplant; 2003 Oct; 32(8):795-800. PubMed ID: 14520424
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
[TBL] [Abstract][Full Text] [Related]
13. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.
Mori T; Okamoto S; Matsuoka S; Yajima T; Wakui M; Watanabe R; Ishida A; Iwao Y; Mukai M; Hibi T; Ikeda Y
Bone Marrow Transplant; 2000 Apr; 25(7):765-9. PubMed ID: 10745263
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients.
von Bueltzingsloewen A; Bordigoni P; Witz F; Bene MC; Schmitt C; Lacour B; Sommelet D
Bone Marrow Transplant; 1993 Sep; 12(3):197-202. PubMed ID: 8241976
[TBL] [Abstract][Full Text] [Related]
15. Use of PCR serum in diagnosing and monitoring cytomegalovirus reactivation in bone marrow transplant recipients.
Matsunaga T; Sakamaki S; Ishigaki S; Kohda K; Takeda M; Katoh J; Kuroda H; Hirayama Y; Kusakabe T; Akiyama T; Kuga T; Niitsu Y; Masaoka T; Sagawa T; Matsumoto Y
Int J Hematol; 1999 Feb; 69(2):105-11. PubMed ID: 10071460
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus surveillance and prevention in allogeneic bone marrow transplantation: examination of a preemptive plan of ganciclovir therapy.
Mandanas RA; Saez RA; Selby GB; Confer DL
Am J Hematol; 1996 Feb; 51(2):104-11. PubMed ID: 8579049
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience.
Manteiga R; Martino R; Sureda A; Labeaga R; Brunet S; Sierra J; Rabella N
Bone Marrow Transplant; 1998 Nov; 22(9):899-904. PubMed ID: 9827819
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
Ahsan N; Holman MJ; Yang HC
Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
[TBL] [Abstract][Full Text] [Related]
19. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir.
Bacigalupo A; van Lint MT; Tedone E; Moro F; Sanna MA; Longren M; Trespi G; Frassoni F; Occhini D; Gualandi F
Bone Marrow Transplant; 1994 Jun; 13(6):753-8. PubMed ID: 7920310
[TBL] [Abstract][Full Text] [Related]
20. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy.
Machado CM; Dulley FL; Boas LS; Castelli JB; Macedo MC; Silva RL; Pallota R; Saboya RS; Pannuti CS
Bone Marrow Transplant; 2000 Aug; 26(4):413-7. PubMed ID: 10982288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
